^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IFNAR1 (Interferon (alpha, beta and omega) receptor 1)

    i
    Other names: IFNAR1, IFNAR1, Interferon (alpha, beta and omega) receptor 1
    6d
    Upstream ORFs control TNFR1 abundance and tissue tolerance to TNF. (PubMed, Sci Immunol)
    We additionally report that the translation of other immune receptor messenger RNAs, including TLR4, IFNAR1, and IFNGR2, is also controlled by uORFs. Thus, regulation of TNFR1 levels and possibly of other immune receptors emerges as a mechanism safeguarding against excessive immune responses and tissue damage.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • TLR4 (Toll Like Receptor 4) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)
    15d
    Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction. (PubMed, Nat Commun)
    Consistently, normal breast epithelium displays membrane-localized TYK2, whereas invasive breast tumors exhibit cytoplasmic TYK2. These findings uncover a TYK2-dependent mechanism by which ECM rigidity suppresses breast cancer metastasis and underscore the need for breast cancer screening in patients receiving TYK2 inhibitors.
    Journal
    |
    TYK2 (Tyrosine Kinase 2) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    23d
    Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice. (PubMed, Nat Commun)
    Finally, to mitigate IFNα-induced toxicity, we engineer a Pro-BiDT engager featuring a pro-IFNα and report potent antitumor activity with reduced systemic toxicity. Thus, by bridging DC-T cells together, BiDT treatment enhances the critical communication pathways and cellular circuits necessary for effective anti-tumor immunity.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL2 (Interleukin 2) • IFNA1 (Interferon Alpha 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • CD80 (CD80 Molecule)
    26d
    PIN1 suppresses bladder cancer progression by inducing cellular senescence and activating the interferon response pathway. (PubMed, Cell Signal)
    Our study reveals PIN1 as a previously unrecognized bladder-cancer tumor suppressor that halts progression by provoking senescence and re-awakening interferon signaling. This work rewrites the molecular landscape of the disease and positions PIN1 as both a prognostic indicator and a druggable node for future therapies.
    Journal
    |
    IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • IRF7 (Interferon Regulatory Factor 7) • PIN1 (Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1)
    27d
    DPP9 inhibition boosts antitumor immunity by disrupting BRISC-mediated PD-L1 expression in clear cell renal cell carcinoma. (PubMed, Cell Death Differ)
    Moreover, the combination of 1G244 and anti-CTLA-4 therapy further enhanced antitumor immunity, highlighting a potential synergistic therapeutic strategy. Collectively, our findings define a novel DPP9-BRISC-SHMT2 regulatory axis in PD-L1 transcriptional control and identify 1G244 as an alternative combinatorial strategy to enhance the efficacy of cancer immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • SHMT2 (Serine Hydroxymethyltransferase 2)
    |
    PD-L1 expression
    1m
    Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling. (PubMed, J Immunother Cancer)
    Overall, the data demonstrate that RP1 remodels the tumor microenvironment through a combination of direct and indirect effects on both tumor and immune cells, resulting in an overall more inflamed phenotype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CSF2 (Colony stimulating factor 2) • ITGAM (Integrin, alpha M) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    PD-L1 expression
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    2ms
    ENPP3 drives ccRCC progression by cGAMP hydrolysis and STING-IFN suppression. (PubMed, Cancer Biol Ther)
    ENPP3 is a hypoxia-driven, cGAMP-targeting innate immune checkpoint in ccRCC. Its inhibition reactivates STING-dependent anti-tumor immunity, providing a strong preclinical rationale for targeting ENPP3 therapeutically.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • STING (stimulator of interferon response cGAMP interactor 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    2ms
    The amplitude of gammaherpesvirus lytic replication dictates adaptive immune activation: Potential implications for KSHV LANA in immune evasion. (PubMed, bioRxiv)
    Using this chimeric MHV68 virus, we demonstrate that lytic viral amplification must breach a threshold to trigger a potent virus-specific adaptive immune response. We propose that KSHV, through LANA, evades detection by repressing lytic viral replication to remain "below the radar" of adaptive immune defenses during host colonization.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    Akeega (abiraterone/niraparib)
    2ms
    Exosome RAB10 inhibits JAK1/STAT1 to hinder macrophage M1 polarization and promote tumor immune escape. (PubMed, Cell Commun Signal)
    RAB10 interacts with IFNAR1 to suppress the JAK1/STAT1 signaling pathway, thereby inhibiting M1 polarization and promoting M2 polarization of macrophages. Inhibition of RAB10, especially in combination with PD-L1 blockade, offers a promising strategy to enhance anti-tumor immunity and overcome therapeutic resistance in breast cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1) • MMP2 (Matrix metallopeptidase 2) • VIM (Vimentin) • PCNA (Proliferating cell nuclear antigen) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • RAB10 (RAB10, Member RAS Oncogene Family)
    3ms
    Multivalent display of Envelope protein domain III with Mi3 nanoparticles induces protective immunity against lethal Zika virus infection in mice. (PubMed, Virol Sin)
    Notably, unlike ZIKV convalescent sera, Mi3-EDIII immune sera did not enhance DENV infection in human chronic myelogenous leukemia K562 cells, suggesting the absence of ADE-prone antibody induction. Our results demonstrate that Mi3-EDIII is a promising vaccine candidate against ZIKV infection and warrants further development.
    Preclinical • Journal
    |
    IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    3ms
    Inhibition of type I interferon signaling is a conserved function of gamma-herpesvirus-encoded microRNAs. (PubMed, J Virol)
    Evading anti-viral responses is a key component of long-term viral persistence. In this work, we show that small noncoding RNAs expressed by multiple non-human primate γ-herpesviruses regulate anti-viral responses by directly targeting components of the type I interferon (IFN) signaling pathway.
    Journal
    |
    JAK1 (Janus Kinase 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)
    4ms
    STAT2 Promotes Tumor Growth in Colorectal Cancer Independent of Type I IFN Receptor Signaling. (PubMed, Curr Oncol)
    However, in xenograft tumor transplantation models, IFNAR1 KO cells formed larger tumors while STAT2 KO tumor cells formed smaller ones compared to parental tumor cells. These findings indicate that STAT2 promotes colorectal cancer growth through mechanisms independent of IFNAR1 signaling.
    Journal
    |
    IFNAR1 (Interferon (alpha, beta and omega) receptor 1) • STAT2 (Signal transducer and activator of transcription 2)